Literature DB >> 30291899

Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery.

Younis Baqi1, Christa E Müller2.   

Abstract

The P2Y12 receptor is one of eight known P2Y receptor subtypes, and belongs to the G-protein-coupled receptor (GPCR) family. The P2Y12 receptor is highly expressed on blood platelets and in the brain. Potent, selective, peripherally acting antagonists for the P2Y12 receptor are used clinically as antithrombotic drugs. Several different scaffolds have been identified as P2Y12 receptor antagonists, including irreversibly acting thienotetrahydropyridines (prodrugs), and reversible competitive antagonists, including adenine nucleotide analogs, piperazinyl-glutamate-quinolines, -pyridines, and -pyrimidines, and anthraquinone derivatives. Here, we provide an overview of the different scaffolds that have been developed as P2Y12 receptor antagonists, some of which have become important therapeutics.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30291899     DOI: 10.1016/j.drudis.2018.09.021

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  10 in total

1.  Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a target trial using multiple national Swedish registries.

Authors:  Georg Hans Kuhn; Frederick R Walker; Michael Nilsson; Madeleine Hinwood; Jenny Nyberg; Lucy Leigh; Sara Gustavsson; John Attia; Christopher Oldmeadow; Marina Ilicic; Thomas Linden; N David Åberg; Chris Levi; Neil Spratt; Leeanne M Carey; Michael Pollack; Sarah J Johnson
Journal:  BMJ Open       Date:  2022-05-09       Impact factor: 3.006

Review 2.  Update of P2Y receptor pharmacology: IUPHAR Review 27.

Authors:  Kenneth A Jacobson; Esmerilda G Delicado; Christian Gachet; Charles Kennedy; Ivar von Kügelgen; Beibei Li; M Teresa Miras-Portugal; Ivana Novak; Torsten Schöneberg; Raquel Perez-Sen; Doreen Thor; Beili Wu; Zhenlin Yang; Christa E Müller
Journal:  Br J Pharmacol       Date:  2020-04-06       Impact factor: 9.473

Review 3.  From purines to purinergic signalling: molecular functions and human diseases.

Authors:  Zhao Huang; Na Xie; Peter Illes; Francesco Di Virgilio; Henning Ulrich; Alexey Semyanov; Alexei Verkhratsky; Beata Sperlagh; Shu-Guang Yu; Canhua Huang; Yong Tang
Journal:  Signal Transduct Target Ther       Date:  2021-04-28

4.  Effects of diagnostic ultrasound with cRGD-microbubbles on simultaneous detection and treatment of atherosclerotic plaque in ApoE-/- mice.

Authors:  Shengcun Guo; Shengye Zhang; Kui Chen; Xi Chen; Fudong Hu
Journal:  Front Cardiovasc Med       Date:  2022-07-22

Review 5.  P2 Receptors: Novel Disease Markers and Metabolic Checkpoints in Immune Cells.

Authors:  Valentina Vultaggio-Poma; Francesco Di Virgilio
Journal:  Biomolecules       Date:  2022-07-14

Review 6.  Carbohydrate-based drugs launched during 2000-2021.

Authors:  Xin Cao; Xiaojing Du; Heng Jiao; Quanlin An; Ruoxue Chen; Pengfei Fang; Jing Wang; Biao Yu
Journal:  Acta Pharm Sin B       Date:  2022-05-23       Impact factor: 14.903

Review 7.  Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.

Authors:  Thiago Dominguez Crespo Hirata; Carolina Dagli-Hernandez; Fabiana Dalla Vecchia Genvigir; Volker Martin Lauschke; Yitian Zhou; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Mol Diagn Ther       Date:  2021-08-06       Impact factor: 4.074

Review 8.  P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation.

Authors:  Alexandre Mansour; Christilla Bachelot-Loza; Nicolas Nesseler; Pascale Gaussem; Isabelle Gouin-Thibault
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

Review 9.  P2 Purinergic Signaling in the Distal Lung in Health and Disease.

Authors:  Eva Wirsching; Michael Fauler; Giorgio Fois; Manfred Frick
Journal:  Int J Mol Sci       Date:  2020-07-14       Impact factor: 5.923

Review 10.  Recommended tool compounds and drugs for blocking P2X and P2Y receptors.

Authors:  Christa E Müller; Vigneshwaran Namasivayam
Journal:  Purinergic Signal       Date:  2021-09-02       Impact factor: 3.765

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.